Dr. Brown on the Promise of the ROCSAN Trial in Gynecologic Carcinosarcomas

Partner | Cancer Centers | <b>Atrium Health Levine Cancer Institute</b>

Jubilee Brown, MD, discusses the promise of the phase 2/3 ROCSAN trial in recurrent gynecologic carcinosarcomas.

Jubilee Brown, MD, professor, director, Gynecologic Oncology, Levine Cancer Institute, Atrium Health, discusses the promise of the phase 2/3 ROCSAN trial (NCT03651206) in recurrent gynecologic carcinosarcomas.

The multicenter ROCSAN trial is currently enrolling patients with metastatic or recurrent endometrial or ovarian carcinosarcoma who have received at least 1 line of prior chemotherapy. Patients are randomized 2:2:1 to niraparib (Zejula), niraparib plus dostarlimab, or physician’s choice chemotherapy.

Although data have not yet emerged from the study, the combination of the PARP inhibitor niraparib and the anti–PD-1 monoclonal antibody dostarlimab is a promising treatment regimen for this patient population, Brown explains. Moreover, because the 3-arm trial is evaluating multiple regimens, the data will answer multiple questions regarding the treatment of patients with gynecologic carcinosarcomas, Brown concludes.